Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for
multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT,
the natural next step is to evaluate maintenance/continuation therapy following second ASCT.
Pomalidomide is active against MM cells refractory to both bortezomib and lenalidomide,
making it an ideal choice for continuation therapy following second ASCT. Adding elotuzumab
may increase efficacy and also the durability of responses which is essential to improving
outcomes following second ASCT.